Tokyo Tape
Sign in
← Chiome Bioscience

Quarterly report · Q3

4583.TEDINET S100S992
Period2023-01-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedNo
Data checks10 of 10 passed
Key figures · 34
MetricValuePeriodScopeSource row
Revenue¥524m2023-01-01 → 2023-09-30StandaloneNet sales
Revenue¥631m2022-01-01 → 2022-12-31StandaloneNet sales (5-year summary)
Revenue¥434m2022-01-01 → 2022-09-30StandaloneNet sales
Operating income−¥905m2023-01-01 → 2023-09-30StandaloneOperating income
Operating income−¥1.0bn2022-01-01 → 2022-09-30StandaloneOperating income
Ordinary income−¥916m2023-01-01 → 2023-09-30StandaloneOrdinary income
Ordinary income−¥1.2bn2022-01-01 → 2022-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.0bn2022-01-01 → 2022-09-30StandaloneOrdinary income
Profit before tax−¥915m2023-01-01 → 2023-09-30StandaloneIncome before income taxes
Profit before tax−¥1.0bn2022-01-01 → 2022-09-30StandaloneIncome before income taxes
Net income−¥918m2023-01-01 → 2023-09-30StandaloneProfit loss
Net income−¥1.2bn2022-01-01 → 2022-12-31StandaloneNet income loss (5-year summary)
Net income−¥1.0bn2022-01-01 → 2022-09-30StandaloneProfit loss
Total assets¥1.8bnat 2023-09-30StandaloneAssets
Total assets¥2.2bnat 2022-12-31StandaloneAssets
Total assets¥2.1bnat 2022-09-30StandaloneTotal assets (5-year summary)
Total liabilities¥542mat 2023-09-30StandaloneLiabilities
Total liabilities¥425mat 2022-12-31StandaloneLiabilities
Net assets / equity¥1.2bnat 2023-09-30StandaloneNet assets
Net assets / equity¥1.8bnat 2022-12-31StandaloneNet assets
Net assets / equity¥1.7bnat 2022-09-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.3bnat 2023-09-30StandaloneCash and deposits
Cash and deposits¥1.7bnat 2022-12-31StandaloneCash and deposits
EPS (basic)¥-18.822023-01-01 → 2023-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-5.152023-07-01 → 2023-09-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-28.262022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-23.872022-01-01 → 2022-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-5.82022-07-01 → 2022-09-30dStandaloneBasic earnings loss per share (5-year summary)
Equity ratio67.8%at 2023-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio80.2%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio78.4%at 2022-09-30StandaloneEquity to asset ratio (5-year summary)
Shares issued50,571,400at 2023-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued48,423,500at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued45,979,100at 2022-09-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-09-30−¥409m
jpcrp040300-q3r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2023-01-01 → 2023-09-30−¥803m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentrevenue2023-01-01 → 2023-09-30¥524m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentrevenue external2023-01-01 → 2023-09-30¥524m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentsegment profit2023-01-01 → 2023-09-30¥307m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-09-30¥524m
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-09-30¥524m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-09-30−¥496m
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-09-30−¥358m
jpcrp040300-q3r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2022-01-01 → 2022-09-30−¥916m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentrevenue2022-01-01 → 2022-09-30¥434m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentrevenue external2022-01-01 → 2022-09-30¥434m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentsegment profit2022-01-01 → 2022-09-30¥235m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-09-30¥434m
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-09-30¥434m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-09-30−¥681m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 329
ItemContextValueUnit
Investments and other assetsCurrentQuarterInstant_NonConsolidatedMember117983000JPY
Noncurrent assetsPrior1YearInstant_NonConsolidatedMember123303000JPY
Noncurrent assetsCurrentQuarterInstant_NonConsolidatedMember119442000JPY
AssetsPrior1YearInstant_NonConsolidatedMember2215470000JPY
AssetsCurrentQuarterInstant_NonConsolidatedMember1753201000JPY
Accounts payable tradePrior1YearInstant_NonConsolidatedMember31866000JPY
Accounts payable tradeCurrentQuarterInstant_NonConsolidatedMember37336000JPY
Short term loans payablePrior1YearInstant_NonConsolidatedMember184000000JPY
Short term loans payableCurrentQuarterInstant_NonConsolidatedMember316300000JPY
Accounts payable otherPrior1YearInstant_NonConsolidatedMember70800000JPY
Accounts payable otherCurrentQuarterInstant_NonConsolidatedMember49729000JPY
Accrued expensesPrior1YearInstant_NonConsolidatedMember26558000JPY
Accrued expensesCurrentQuarterInstant_NonConsolidatedMember23994000JPY
Income taxes payablePrior1YearInstant_NonConsolidatedMember23943000JPY
Income taxes payableCurrentQuarterInstant_NonConsolidatedMember12579000JPY
Advances receivedPrior1YearInstant_NonConsolidatedMember22100000JPY
Advances receivedCurrentQuarterInstant_NonConsolidatedMember31200000JPY
Deposits receivedPrior1YearInstant_NonConsolidatedMember4835000JPY
Deposits receivedCurrentQuarterInstant_NonConsolidatedMember12857000JPY
Provision for bonusesPrior1YearInstant_NonConsolidatedMember6351000JPY
Provision for bonusesCurrentQuarterInstant_NonConsolidatedMember3596000JPY
Current liabilitiesPrior1YearInstant_NonConsolidatedMember370455000JPY
Current liabilitiesCurrentQuarterInstant_NonConsolidatedMember487592000JPY
Asset retirement obligations nclPrior1YearInstant_NonConsolidatedMember54268000JPY
Asset retirement obligations nclCurrentQuarterInstant_NonConsolidatedMember54586000JPY
Noncurrent liabilitiesPrior1YearInstant_NonConsolidatedMember54268000JPY
Noncurrent liabilitiesCurrentQuarterInstant_NonConsolidatedMember54586000JPY
LiabilitiesPrior1YearInstant_NonConsolidatedMember424724000JPY
LiabilitiesCurrentQuarterInstant_NonConsolidatedMember542179000JPY
Capital stockPrior1YearInstant_NonConsolidatedMember2097017000JPY
Capital stockCurrentQuarterInstant_NonConsolidatedMember2262123000JPY
Capital surplusPrior1YearInstant_NonConsolidatedMember3696798000JPY
Capital surplusCurrentQuarterInstant_NonConsolidatedMember3861903000JPY
Retained earningsPrior1YearInstant_NonConsolidatedMember-4016331000JPY
Retained earningsCurrentQuarterInstant_NonConsolidatedMember-4934796000JPY
Treasury stockPrior1YearInstant_NonConsolidatedMember-292000JPY
Treasury stockCurrentQuarterInstant_NonConsolidatedMember-292000JPY
Shareholders equityPrior1YearInstant_NonConsolidatedMember1777192000JPY
Shareholders equityCurrentQuarterInstant_NonConsolidatedMember1188937000JPY
Subscription rights to sharesPrior1YearInstant_NonConsolidatedMember13554000JPY
Subscription rights to sharesCurrentQuarterInstant_NonConsolidatedMember22085000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember1790746000JPY
Net assetsCurrentQuarterInstant_NonConsolidatedMember1211022000JPY
Liabilities and net assetsPrior1YearInstant_NonConsolidatedMember2215470000JPY
Liabilities and net assetsCurrentQuarterInstant_NonConsolidatedMember1753201000JPY
Net salesPrior1YTDDuration_NonConsolidatedMember433694000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember524023000JPY
Cost of salesPrior1YTDDuration_NonConsolidatedMember198703000JPY
Cost of salesCurrentYTDDuration_NonConsolidatedMember216931000JPY
Gross profitPrior1YTDDuration_NonConsolidatedMember234990000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 10 of 10 passed
balance sheet identitynon_consolidated 2022-12-31pass
balance sheet identitynon_consolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-09-30pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-09-30pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-09-30pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2023-09-30pass